Compare RELI & SCNI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RELI | SCNI |
|---|---|---|
| Founded | 2013 | 2003 |
| Country | United States | Israel |
| Employees | 64 | N/A |
| Industry | Specialty Insurers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.5M | 4.6M |
| IPO Year | N/A | N/A |
| Metric | RELI | SCNI |
|---|---|---|
| Price | $0.63 | $0.94 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 2.1M | 41.7K |
| Earning Date | 11-06-2025 | 11-24-2025 |
| Dividend Yield | ★ 4.53% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.26 |
| Revenue | ★ $13,115,995.00 | $1,147,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $4.55 |
| Revenue Growth | N/A | ★ 303.87 |
| 52 Week Low | $0.61 | $0.86 |
| 52 Week High | $5.11 | $6.18 |
| Indicator | RELI | SCNI |
|---|---|---|
| Relative Strength Index (RSI) | 36.84 | 38.13 |
| Support Level | $0.68 | $1.14 |
| Resistance Level | $0.83 | $1.26 |
| Average True Range (ATR) | 0.06 | 0.10 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 2.57 | 13.13 |
Reliance Global Group Inc operates as a holding company with diversified interests in the insurance market, as well as other related sectors. The company focuses on growing by pursuing acquisition strategies, initially and focused on wholesale and retail insurance agencies. Its primary strategies is to identify specific risks to reward arbitrage opportunities and develop these on a national platform, thereby increasing revenues and returns, and then identify and acquire undervalued wholesale and retail insurance agencies with operations in growing or underserved segments, expand and optimize their operations, and achieve asset value appreciation while generating interim cash flows. The company generates revenue in the form of commissions.
Scinai Immunotherapeutics Ltd is a biopharmaceutical company with two complementary business units, one focused on in-house development of inflammation and immunology (I&I) biological therapeutic products beginning with a pipeline of nanosized VHH antibodies (NanoAbs) targeting diseases with large unmet medical needs, and the other a boutique CDMO providing services to help biotech companies efficiently bring their products to market by leveraging Scinai's drug development and GMP and non-GMP manufacturing capabilities for pre-clinical and clinical studies. The company generates maximum revenue from the provision of CDMO (Contract Development and Manufacturing Organization) services.